The content on this site is intended for healthcare professionals only
Dr Le Chevalier speaks about the work carried out at the Gustave-Roussy Institute and the difficulties faced when treating lung cancer. In order to address some of these issues a new institute of thoracic oncology is being established to combine the expertise of both Gustave-Roussy Institute and Centre Chirgical Marie Lannelongue. Dr Le Chevalier discusses research into two promising new drugs currently part of a phase III study; one associated with the EGFR pathway and the other an angiogenesis inhibitor.
Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial
Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
Choosing the right patients for transplant
ESMO 2024: Highlights and analysis
